Palatin Technologies, Inc. — Form 10-Q Summary
Reporting period: Fiscal third quarter and nine months ended March 31, 2021; filed May 14, 2021. The request metadata labels this “2020 Q3,” but the filing covers the quarter ended March 31, 2021 (fiscal 2021 Q3).
Business context
Palatin is a development-stage biopharmaceutical company. Its FDA-approved product, Vyleesi for premenopausal women with hypoactive sexual desire disorder, returned to Palatin’s North American control in July 2020 after termination of the AMAG license. Palatin is now responsible for U.S. marketing, distribution, and manufacturing arrangements. Other programs include melanocortin receptor candidates for inflammatory, autoimmune, obesity, and metabolic indications, and natriuretic peptide candidates.
Key financial metrics
| Metric | Three months ended March 31, 2021 | Nine months ended March 31, 2021 | Comparable 2020 period |
|---|---|---|---|
| Net revenue | $88,741 | $(363,790) | Quarter: $0; nine-month revenue $117,989, all license and contract revenue |
| Operating loss | $(6.49) million | $(19.68) million | $(5.71) million; $(16.22) million |
| Net loss | $(5.73) million | $(19.66) million | $(5.38) million; $(15.13) million |
| Basic and diluted loss per share | $(0.02) | $(0.08) | $(0.02); $(0.06) |
| Cash used in operating activities | Not provided for quarter | $(14.11) million | Nine-month 2020: cash provided of $47.40 million |
- Quarterly product revenue was $88,741 net of $1.69 million in sales allowances against $1.78 million gross sales. Nine-month product revenue was $(363,790) net of $3.90 million in allowances against $3.53 million gross sales.
- Research and development expense was $2.51 million for the quarter and $9.44 million for nine months. Selling, general and administrative expense was $4.01 million and $11.39 million, respectively.
- Cash and cash equivalents were $68.64 million at March 31, 2021, down from $82.85 million at June 30, 2020. Current assets were $79.39 million and current liabilities $10.04 million. Total liabilities were $18.00 million; total stockholders’ equity was $62.88 million.
- The balance sheet reports no notes payable. The prior venture loan had matured, and its final incremental payment was made in July 2019. Operating lease liabilities totaled approximately $1.33 million.
- Vyleesi supply agreements carried $11.07 million of contractual inventory purchase commitments: $3.63 million current, $6.48 million due in one to three years, and $0.96 million in four to five years. Related estimated losses accrued in other current and long-term liabilities totaled approximately $10.60 million.
Material changes versus prior period
- Palatin resumed North American Vyleesi commercialization after the AMAG agreement ended in July 2020. The transition led to product sales, inventory and manufacturing obligations, and higher selling expenses.
- For the nine months, operating cash flow shifted from $47.40 million provided in 2020 to $14.11 million used in 2021. Management attributed the comparison primarily to timing of AMAG-related payments, including payments associated with FDA approval of Vyleesi.
- Nine-month net loss increased to $19.66 million from $15.13 million. Higher SG&A and the absence of prior-period AMAG license revenue contributed; lower R&D expense partly offset the increase.
- For the quarter, net loss rose to $5.73 million from $5.38 million. Quarterly other income included a $753,750 unrealized foreign-currency gain.
- Cash flow and earnings comparisons include unusual AMAG termination-related items: Palatin recorded a $1.62 million net gain for the nine months, while the termination agreement included a $12 million closing payment and a further $4.3 million payment received March 31, 2021.
Outlook, risks and contingencies
- Management said cash and cash equivalents at March 31, 2021 were expected to fund current operating plans for at least 12 months from the financial statements’ issuance. The company expects significant future spending and will need additional funding for required clinical trials and potential regulatory submissions; further financing may not be available on acceptable terms or at all.
- Planned uses of capital include U.S. Vyleesi commercialization and development of MC1r, MC4r, natriuretic peptide, and other programs. The filing provides no quantified revenue or earnings guidance.
- Risks include Vyleesi market acceptance and commercialization, reimbursement, manufacturing and supply commitments, clinical and regulatory outcomes, financing needs, competition, and potential COVID-19 effects on trials, suppliers, operations, and capital access. Palatin also cited foreign-currency exposure on supply commitments denominated in Swiss francs and euros.
- Vyleesi has labeled risks including nausea, transient blood-pressure increases with corresponding heart-rate decreases, and focal hyperpigmentation; it is contraindicated for women with uncontrolled hypertension or known cardiovascular disease.
- Palatin reported no material changes to the risk factors in its fiscal 2020 Form 10-K, no current legal proceedings, and no off-balance-sheet arrangements. Management concluded disclosure controls were effective as of March 31, 2021.
Most important facts for investors to verify
- How Vyleesi gross sales, substantial allowances, returns, and net revenue are developing under Palatin’s direct commercialization model.
- Whether the $68.64 million cash balance and stated 12-month runway remain adequate as operating cash use, commercialization costs, and clinical spending evolve.
- The expected utilization, potential impairment, and cash burden of the $11.07 million supply commitments and related accrued losses.
- Progress and costs for clinical programs, required Vyleesi post-marketing studies, and regulatory and commercialization plans of the China and Korea licensees.
- Potential dilution: 19.81 million stock options and 11.60 million restricted stock units were outstanding at March 31, 2021; the filing excluded 37.34 million potential common shares from diluted EPS as antidilutive.